Literature DB >> 19286302

Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Patrick J Bastian1, Ballentine H Carter, Anders Bjartell, Michael Seitz, Peter Stanislaus, Francesco Montorsi, Christian G Stief, Fritz Schröder.   

Abstract

CONTEXT: Due to early detection strategies, prostate cancer is diagnosed early in its natural history. It remains unclear whether all patients diagnosed with prostate cancer warrant radical treatment or may benefit from delayed intervention following active surveillance.
OBJECTIVE: A systematic review of active surveillance protocols to investigate the inclusion criteria for active surveillance and the outcome of treatment. EVIDENCE ACQUISITION: Medline was searched using the following terms: prostate cancer, active surveillance and expectant management for dates up to October 2008. Further studies were chosen on the basis of manual searches of reference lists and review papers. EVIDENCE SYNTHESIS: Numerous studies on active surveillance were identified. The recent inclusion criteria of the studies are rather similar. Keeping the short follow-up of all studies in mind, the majority of men stay on active surveillance, and the percentage of patients receiving active treatment is as high as 35% of all patients. Once a patients requires active treatment, most patients still present with curable prostate cancer. Furthermore, only few deaths due to prostate cancer have occurred.
CONCLUSIONS: Active surveillance is an alternative option to immediate treatment of men with presumed insignificant prostate cancer. It seems that criteria used to identify men with low-risk prostate cancer are rather similar, and immediate treatment of men meeting these criteria may result in an unnecessary number of treatments in these highly selected patients. Data from randomised trials comparing active surveillance and active treatment will provide additional insight into outcome and follow-up strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286302     DOI: 10.1016/j.eururo.2009.02.028

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  56 in total

1.  Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.

Authors:  Leslie Oleksowicz; Yin Liu; R Bruce Bracken; Krishnanath Gaitonde; Barbara Burke; Paul Succop; Linda Levin; Zhongyun Dong; Shan Lu
Journal:  Prostate       Date:  2011-11-29       Impact factor: 4.104

Review 2.  Nuclear morphometry, nucleomics and prostate cancer progression.

Authors:  Robert W Veltri; Christhunesa S Christudass; Sumit Isharwal
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

3.  Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.

Authors:  Trevor A Flood; Nicola Schieda; Daniel T Keefe; Rodney H Breau; Chris Morash; Kevin Hogan; Eric C Belanger; Kien T Mai; Susan J Robertson
Journal:  Virchows Arch       Date:  2016-07-10       Impact factor: 4.064

4.  Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS).

Authors:  Ekaterina Lellig; Christian Gratzke; Alexander Kretschmer; Christian Stief
Journal:  World J Urol       Date:  2015-06-06       Impact factor: 4.226

5.  Prostate cancer: treatment triggers for patients on active surveillance.

Authors:  William M Hilton; Dipen J Parekh
Journal:  Nat Rev Urol       Date:  2011-01-18       Impact factor: 14.432

6.  Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue.

Authors:  Jeffrey R Shuster; Raymond S Lance; Dean A Troyer
Journal:  BMC Clin Pathol       Date:  2011-12-21

7.  Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies.

Authors:  Bumsoo Park; Seong-Soo Jeon; Sung-Ho Ju; Byong-Chang Jeong; Seong-Il Seo; Hyun-Moo Lee; Han-Yong Choi
Journal:  Asian J Androl       Date:  2012-12-31       Impact factor: 3.285

8.  Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring.

Authors:  Jenny L Donovan
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

Review 9.  Active surveillance in prostate cancer: the need to standardize.

Authors:  Xavier Filella; Juan Alcover; Rafael Molina
Journal:  Tumour Biol       Date:  2011-05-28

Review 10.  Does true Gleason pattern 3 merit its cancer descriptor?

Authors:  Saiful Miah; Hashim U Ahmed; Alex Freeman; Mark Emberton
Journal:  Nat Rev Urol       Date:  2016-08-17       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.